Sandoz announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed rituximab biosimilar. The drug is referenced on Rituxan, which is approved to treat blood cancers and immunological diseases.
Sandoz announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed rituximab biosimilar. The drug is referenced on Rituxan, which is approved to treat blood cancers and immunological diseases.
The BLA’s data package includes analytical, preclinical, and clinical data, including a pharmacokinetic and pharmacokinetic trial of the proposed drug in the ASSIST-RA rheumatoid arthritis trial phase 3 confirmatory safety and efficacy data from the ASSIST-FL follicular lymphoma study.
Sandoz says that it hopes its drug will, if approved, help reduce the high cost of biologic treatment. “The cost of treating cancer in the [United States] is a major concern for many patients and their families as well as for the healthcare system,” said Mark Levick, MD, PhD, global head of biopharmaceuticals development for Sandoz. “With the FDA acceptance of our regulatory submission for proposed biosimilar rituximab, we plan to…[free] up resources for and [support] patient access in other areas of cancer care including innovative therapies.”
In June, Sandoz received approval from the European Commission to market its rituximab biosimilar in Europe. Under the name Rixathon, Sandoz’s product is approved to treat all indications of the reference rituximab. Sandoz called the product 1 of 5 major launches the company has planned for the coming 4 years.
While the reference rituximab already faces competition from biosimilars in Europe, the global market for the drug has continued to grow; the branded drug earned $8.58 billion for Genentech in 2016, an increase of 2.7% from its 2015 sales.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.